The third FDA-cleared Alzheimer's blood-biomarker test, a blood measure of amyloid buildup, is C2N Diagnostics' PrecivityAD2 for adults 40 and older with cognitive symptoms. Cleared Aug. 20, 2026, it aids diagnosis during clinician-led evaluation of symptoms, not routine screening of healthy adults.
According to C2N Diagnostics, the clearance makes PrecivityAD2 the third cleared test and the first cleared for symptomatic adults as young as 40 C2N Diagnostics announcement. The test helps rule amyloid pathology, the Alzheimer's-related protein buildup, in or out at early stages. Readers benefit most by matching personal symptoms to the labeled use before acting.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Roche — Use this primary source to verify the official guidance.
Table of Contents
- What the clearance allows
- How it differs from earlier cleared tests
- Why this is not screening for healthy adults
- What to do if memory symptoms are new
What the clearance allows
The Alzheimer's Association describes PrecivityAD2 for adults 40 and older with signs or symptoms of cognitive impairment. It aids Alzheimer's diagnosis together with history, exam, and other standard workup. It does not replace that workup.
C2N Diagnostics reports the test uses high-resolution mass spectrometry and a multi-analyte algorithm score. Mass spectrometry is a precise lab method that measures tiny blood proteins. The combined score helps rule amyloid pathology in or out at early stages.
How it differs from earlier cleared tests
VA-News reports two earlier clearances with a higher age limit comparison of the earlier clearances. They were Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 ratio in May 2025 and Roche's Elecsys pTau181 in Oct. 2025, both for ages 55 and older. PrecivityAD2 lowers the labeled age to 40 for people with symptoms.
Roche announced FDA clearance on Aug. 24, 2026, for its single-biomarker Elecsys Phospho-Tau 217P plasma test. It assesses amyloid pathology in people 55 and older with cognitive signs or complaints. PrecivityAD2 instead uses a multi-analyte score and covers symptomatic adults from age 40.
Why this is not screening for healthy adults
The Alzheimer's Association explains these tests are for symptomatic evaluation alongside clinical assessment, not routine testing of healthy adults Alzheimer's Association guidance. The headline overreads when it suggests checkup screening or self-testing. Clinical context determines what a result means.
A low score alone does not explain memory symptoms without exam and history. A high score still needs clinician review and possible confirmatory testing. Skipping that step risks needless worry or false reassurance.
What to do if memory symptoms are new
The Alzheimer's Association advises seeing a clinician experienced in cognitive-impairment evaluation. That clinician can combine history, exam, and the blood result. That same visit can arrange confirmatory testing or follow-up rather than leaving you to self-interpret.
The Alzheimer's Association 2025 clinical practice guideline notes tests with at least 90 percent sensitivity and at least 90 percent specificity can substitute for PET or CSF testing 2025 clinical practice guideline. PET is a brain scan that shows amyloid, while CSF is a spinal-fluid test. Lower-accuracy positive results should be confirmed by CSF or amyloid PET.
- Write down specific symptom examples, timing, and impact on daily tasks
- Bring medication list, medical history, and a person who has seen the changes
- Ask whether your result needs confirmation or watchful follow-up
- Book follow-up to review results with that clinician
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Adults With New Memory Symptoms Can Avoid Overreading the Headline
- Food Access and Brain Health Research Priorities in 2026: Questions Adults With Memory Concerns Can Ask About the Research
